Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The most common mutation in CF, an inframe deletion of phenylalanine 508, leads to a trafficking defect and endoplasmic reticulum retention of the protein where it becomes targeted for degradation. Successful clinical deployments of ivacaftor and ivacaftor/lumacaftor combination have been an exciting translational development in treating CF. However, their therapeutic effects are variable between subjects and remain insufficient. We used the Library of Integrated Network-based Cellular Signatures (LINCS) database as our chemical pool to screen for candidates. For in silico screening, we integrated connectivity mapping and CF systems biology to identify candidate therapeutic compounds for CF. Following in silico screening, we validated our candidate compounds with (i) an enteroid-based compound screening assay using CF (ΔF508/ΔF508-CFTR) patient-derived enteroids, (ii) short-circuit current analysis using polarized CF primary human airway epithelial cells and (iii) Western blots to measure F508-del-CFTR protein maturation. We identified 184 candidate compounds with in silico screening and tested 24 of them with enteroid-based forskolin-induced swelling (FIS) assay. The top hit compound was PP2, a known src-kinase inhibitor that induced swelling in enteroid comparable to known CF corrector (lumacaftor). Further validation with Western blot and short-circuit current analysis showed that PP-2 could correct mutant CFTR mis-folding and restore CFTR-mediated transmembrane current. We have identified PP2, a known src-kinase inhibitor, as a novel corrector of Δ F508-CFTR. Based on our studies and previous reports, src kinase inhibition may represent a novel paradigm of multi-action therapeutics -corrector, anti-inflammatory, and antiinfective -in CF.
Background
Cystic fibrosis (CF) is a life-limiting genetic disorder affecting 70,000 individuals worldwide (about 30,000 in the United States). Although the recent drug approvals for CF (potentiator ivacaftor alone and in combination with corrector lumacaftor) are promising, the pursuit for additional therapeutics for CF needs to be continued [1] for the following reasons. In vitro studies have shown that the approved combinatorial has limited clinical efficacy with potential interference of potentiator (augment CFTR channel function) with corrector (promote the readthrough of nonsense mutations or facilitate the translation, folding, maturation, and trafficking of mutant CFTR to the cell surface) actions and destabilization of corrected Δ F508-CFTR, the most common mutant in CF [2] [3] [4] . Additionally, apart from being cost-prohibitive (>$250K/year), the approved combinatorial will not work for all CF patients [2, 3, 5, 6] . The context of various CFTR mutations (>2000), the complexity of the underlying pathways, and pathway cross-talk suggest that a computational big data approach that uses high-throughput experimental data and systems biology attributes could lead to the discovery of hitherto unanticipated potential targets and therapeutic candidates for CF. Indeed, mining some of the genomics and small-molecule data silos (e.g., disease/drug gene expression profiles or signatures) in an integrative manner has already been shown to be of translational benefit such as finding novel drug-drug and drugdisease relationships [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . However, a majority of such signature comparison-based approaches treats cells as black boxes; gene expression patterns from small-molecule treatments and from patients or disease models are the inputs and a ranked list of compounds is the output.
Further, the output from such computational analysis is often large, necessitating further prioritization. Thus, there is a critical and unmet need to triage small molecules discovered from high-throughput screens for further development so that investigators can focus on a smaller number with greater success and lower cost. By incorporating additional layers of systems biology attributes (e.g., wild type and mutant CFTR-specific protein interactions and CF-relevant signaling networks and pathways), the current study sought to unveil the internal configuration of the black box underlying the connected small molecules, their targets, and CF disease gene signatures. Such understanding could lead to identifying new therapeutics, drug targets, and target pathways and novel mechanisms of action for CF. Additionally, doing these studies earlier in the drug discovery pipeline could help in potentially foreseeing or avoiding late-stage clinical trial failures. Since the compound screening framework in the current study includes approved drugs, drug repositioning candidates for CF might also be found.
The CF gene expression signature derived from rectal epithelia (RE) of human CF patients with ∆ F508-CFTR mutation [18] was used to search the Library of Integrated Network-based Cellular Signatures (LINCS) database [19, 20] to identify compounds that are anti-correlated with the CF signature. We then complemented this unbiased chemical signature-based screening method with CF knowledge-based systems biology approaches to characterize and infer mechanistic insights.
Finally, we tested computationally prioritized small molecules from this integrated approach in vitro for their effect on fluid secretion (in the presence and absence of CF-corrector VX809) by using intestinal organoids (enteroids or miniguts) generated from the intestines of Δ F508-CFTR homozygous mice and CF patients. Additional candidate compounds were validated by measuring the CFTR-dependent short circuit currents (I sc ) by using polarized CF primary human airway epithelial cells [21, 22] .
Methods

Differentially expressed genes in CF
Microarray data of rectal epithelial cells from healthy volunteers and from CF patients with ∆ F508-CFTR mutation (homozygous) were downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) [23] . Differential analysis for genes was performed using the R package limma with P=0.05 and fold change threshold at 1.5 [24] .
Computational small-molecule compound screening
We used the LINCS cloud web tool [20] and gene set enrichment analysis (GSEA) to identify small molecules from the NIH's LINCS library that could potentially reverse the CF gene expression profile. LINCS signatures (460,000) were downloaded from LINCScloud (www.lincscloud.org) using API. Each signature consisted of a list of 100 most up-regulated and 100 most down-regulated probes. The original ConnectivityMap method [14] was applied to a CF disease signature against each of the 460,000 LINCS signatures to calculate a connectivity score. This resulted in 460,000 LINCS Connectivity Scores for each CF disease signature. Since in LINCS experiment the same treatment was applied in multiple cell lines with different duration and dosages, they were all considered biological replicates of the same treatment in the current analysis. Therefore, a non-parametric two sample Kolmogorov-Smirnov test was used to compare the Connectivity Scores of signatures from one treatment against the background Connectivity Scores of the entire 460,000 LINCS signatures. Since we were interested in the compound whose signature was inversely correlated to the CF disease signature, the one-tailed KS test was applied wherein the alternative hypothesis was that the Connectivity Scores of the underlying treatment were higher than the background Connectivity Scores (note that negative Connectivity Score indicates reverse relation between the treatment and CF disease signature).
This one-tailed two sample KS test was performed for each unique compound treatment, and the resulting p-value was reported as the significance of the compound. This p-value was then used to rank all compound treatments in LINCS. The complete process was performed using R environment. LINCS signatures were downloaded using "jsonlite" package [25] .
Computational modeling of
∆
F508-CFTR and docking of PP2 and VX-809
Open-state WT CFTR structure was obtained from a previous work by Dalton et al. [26] . ∆ F508-CFTR mutant structure was predicted by Modeller9v18 [27] using wild type structure as a template. Three-dimensional ligand structures of VX-809 and PP2 were obtained from PubChem [28] , and adding hydrogens to the receptor and assigning Gasteiger charges to the protein and the compounds were done by AutoDockTools [29] .
Reagents and antibodies
PP2 and other compounds tested were purchased from Tocris Bioscience (Ellisville, Missouri) while VX-809 and VX-661 were obtained from Selleck (Houston, Texas).
Human studies
Human intestinal biopsy and lung tissues were obtained from CFTRWT/WT non-CF and 
Enteroid cultures
Mouse intestinal organoids were cultured as described previously (25) Mucosa is gently scraped with curved forceps to remove villi and debris followed by 3-4 washes with DPBS. Crypts were dissociated using 2 mM EDTA (30 min, 4°C with gentle shaking)
followed by gentle scraping of the mucosa. The crypt suspension was filtered through a 150 µm nylon mesh twice and pelleted at 50 X g, 4°C. The crypt pellet was resuspended in matrigel matrix (200 to 500 crypts/50 µl matrigel per well of a 24 well plate). Matrigel was allowed to polymerize by placing the plate in a 37°C, 5% CO2 incubator for 30 min followed by addition of complete growth factor supplemented human minigut medium (Advanced DMEM/F12 medium with 2 mM glutamine, 10 mM HEPES, 100 U/mL penicillin, 100 g/mL streptomycin, 1 N2 supplement, 1 B27 supplement and 1% BSA supplemented with 50% Wnt-3A-conditioned medium, 1 µg/ml R-spondin 1, 100 ng/ml Noggin. 50 ng/mL EGF, 500 nM A-83-01, 10 µM SB202190, 10 nM [Leu]15-Gastrin 1, 10 mM Nicotinamide and 1 mM N-Acetylcysteine.
Fluid secretion measurement in intestinal spheroids
Isolation of intestinal spheres and measurement of fluid secretion were performed as described previously [30] . Day 1-4 intestinal organoids were treated with 0.1-10 µM of the test compound for 24 h before stimulation of CFTR function using forskolin (10 µM). Fluid secretion measurements were done before and after 30 min of a stimulation period for mouse organoids and 120 min for human organoids. Quantitation of fluid secretion in the intestinal spheres was performed as described previously [30, 31] . 
PP2 RNA-Seq
RNA sequencing was performed on primary human bronchial epithelial cells homozygous for ∆ F508-CFTR mutation (sample ID KKCFFT004I, Charles River, Wilmington, MA). Briefly, fully differentiated bronchial epithelial cells maintained on air-liquid interface were treated with DMSO or PP2 (2 µM, 24 h). Total RNA was isolated using mirVana™ miRNA Isolation Kit (Carlsbad, California) and used for RNA sequencing.
Results
Identifying candidate anti-CF small molecules through integrated gene expression profiling and systems biology
We used a published CF patient gene expression data set (GSE15568; [18] , which was based on rectal epithelia samples of CF patients with Δ F508-CFTR mutation. Differential analysis of gene expression was performed by the R package 'limma' with P-value threshold at 0.05 and fold change threshold at 1.5 [24] . Compared with healthy controls, 1330 genes were differentially expressed in ∆ F508-CF patients. Among these genes, 555 were downregulated, and 775 were upregulated (Additional file 1). We used this differentially expressed gene (DEG) set to identify small molecules from the NIH's LINCS library that could potentially reverse the CF gene expression profile. We used the LINCS cloud web tool and gene set enrichment analysis (GSEA) for this purpose (Fig. 1) . Following this signature reversal step, 184 compounds were identified as significantly reversing the CF disease signature.
To elucidate computationally each of the 184 compounds, specifically to determine their putative functional relatedness to CFTR protein (WT or ∆ F508) interactome [32] and to compiled CFrelevant pathways (Additional file 2, see Methods), we performed a singular enrichment analysis (SEA) by using the DEGs of each of these compounds in the A549 cell lines available from the LINCS database. Eight compounds that were not enriched in any of the CF-relevant pathways were removed from the candidate list of compounds. To further narrow the candidates potentially involved in CF, we selected 10 pathways that were highly related with CF pathogenesis and ranked all the remaining compounds based on their average enrichment p-values in these terms.
To diversify our selection, we also selected a few compounds with low ranking scores. ( Fig. 3B) .
Screening of PP2 and its non-src-kinase-inhibitor analog PP3 using enteroids derived from CF patients (ΔF508/ΔF508-CFTR)
The corrector potential of PP2 could be recapitulated in CF (ΔF508/ΔF508-CFTR) patientderived duodenal organoids. PP2 induced significant FIS at doses of 2 µM, and the enteroid swelling induced by PP2 was comparable to that by VX-809. To examine the dependence of PP2-mediated FIS on src kinase inhibition, we included PP3, an inactive PP2 analog, in our CFTR assay; the analog failed to mediate FIS (Fig. 4A ).
PP2 corrected
Δ
F508-CFTR mutant protein
Since we observed that PP2 functionally rescued (Fig. 4C ).
Computational modeling of ∆
F508-CFTR and PP2
To predict the PP2 mode of action (MoA), we docked PP2 and VX-809 to ∆ F508-CFTR and compared binding poses and affinities. Predicted binding affinities of PP2 and VX-809 by Autodock4 to the NBD1:ICL4 interface was -7.92 kcal/mol and -10.00 kcal/mol, respectively. In the case of the ATP binding site, the binding affinities for PP2 and VX-809 were -8.47 and -11.14 kcal/mol, respectively. These results suggest that PP2 might bind to the ATP binding site.
The predicted binding pose of VRT-325 and PP2 is illustrated in Fig. 4D . Further, the heterobicyclic aromatic rings of PP2 positioned at the same place in the binding pocket, supporting our hypothesis that PP2 binds to the ATP site. To further compare the binding affinity of PP2 to the ATP binding site, we docked PP2 with four known binders (Fyn, Hck, Lck, and Src). Interestingly, the predicted binding affinities between PP2 and the four kinases were weaker than for PP2 and ATP binding site of CFTR. For instance, although the Lck protein is cocrystalized with PP2 (1QPE), its binding affinity was ~1.8 kcal/mol lower than the ATP binding site of CFTR. This result strongly suggests that PP2 binds to the ATP binding site of CFTR.
Characterization of PP2 as candidate therapeutic for CF
To gain insight into the mechanism of ∆ F508-CFTR correction by PP2 in the context of CF pathophysiology, we analyzed the transcriptional profile of PP2 (from both LINCS and CF RNASeq data) along with CF DEGs.
We first analyzed the top upregulated and downregulated genes from PP2-treated cells (LINCS L1000 data) and DEGs from CF RE. Specifically, using our compiled CF-and CFTR-relevant biological processes, pathways, [33] which were downregulated by PP2. Among them, MMP-9 and MMP-12 had increased activity in CF patients [34, 35] , and increased MMP-9 activity was negatively correlated with lung function [36] . PP2 also downregulated genes involved in CF-related pathway macrophage activation including INHBA, IL1A, and FN1. This is important because leukocyte inflammation in the airway is associated with increased CF severity in patients [37] . On the other hand, PP2 upregulated and restored expression of CFI, C1R, and C1S, which are involved in classical complement activation. This is potentially therapeutic since complement activation helps contain bacterial infection, which is an important contributing factor for CF pathogenesis in the lung [38, 39] . Taken together, these results suggest that PP2 could potentially protect the airway from inflammation and proteolytic damage in CF patients in addition to correcting the fundamental defect of mutant CFTR in CF (Fig. 7) .
Discussion
In this study, we described a CF-specific systems biology-guided unbiased computational compound screening to identify and prioritize novel small molecules that could potentially rescue ∆ F508-CFTR function. Using enteroids generated from the ileum of While we observed synergy with VX-809, the potential side effects of PP2 in combination with VX-809 (or VX-661) are difficult to predict. Further, we noted that PP2, like most other srckinase inhibitors, might be mechanistically associated with drug-induced side effects. Thus, thorough toxicity tests in animal models followed by clinical studies of PP2 and the combinations (PP2 and VX-809/VX-661) would have to be performed.
Although we tested 24 compounds from a total of 184 candidates, we believe that additional CF candidate therapeutics can be identified from the remaining nontested compounds. For instance, among the remaining 160 compounds, we further prioritized 30 compounds that are highly similar to both PP2 and LY-294002 as CF candidate therapeutics (Additional file 7).
Although results from our in vitro analysis and computational docking (Figs. 4B and 4D) suggest potential direct action of PP2 on mutant CFTR, additional in vitro and in vivo analysis are warranted. For instance, is the PP2-induced mutant CFTR correction dependent on the canonical SFK (src family kinase) inhibition? SFKs have important roles in biological processes altered in CF such as apoptosis, inflammatory response, autophagy and mucin production, although the exact relation between SFK and these processes in the context of CF remain largely unknown [43] . A recent study showed that CFTR deficiency leads to SFK self-activation and intensified inflammatory response in mouse cholangiocytes exposed to endotoxin or LPS, and inhibition of SFK with PP2 decreased inflammation [44] . This is in consistence with our results wherein we found that PP2 downregulated genes in human CFBE showed an enrichment (P<0.05) for macrophage activation markers (Additional file 5) such as INHBA, IL1A, MMP12, MMP9, and FN1, suggesting that PP2 may potentially ameliorate SFK-triggered inflammatory cascades.
Recurrent Pseudomonas aeruginosa (PsA) infection is a major contributor to CF pathology [45] .
Previous studies [46] have shown that Lyn, an SFK member is critical for PsA internalization into lung cells and that blocking the activity of Lyn with PP2 prevented PsA internalization. It has also been shown that the NLRP3 inflammasome is mediated by SFK activity [47] and that NLRP3 activation exacerbates the PsA-driven inflammatory response in CF [48] and NLRP3 inflammasomes are potential targets to limit the microbial colonization in CF [49] . Additionally, it has been reported that PsA infection induces the expression of MMPs (MMP12 and MMP13), which further exacerbates chronic lung infection and inflammation [50, 51] . In our study, we found PP2 downregulated MMPs and NLRP3 in CFBE treated with PP2 (Additional file 5), suggesting PP2 could also be therapeutic in CF though inhibition of PsA infection.
Conclusions
In addition to novel candidate drugs to target mutated CFTR, novel anti-inflammatory and antiinfective drugs that address secondary disease pathology in CF are needed to lessen morbidity, prolong survival, and improve quality of life [52, 53] . Thus, although additional studies are required, our results suggest that the SFK-inhibition (e.g., PP2) may represent a novel paradigm of multi-action therapeutics -corrector, anti-inflammatory, and anti-infective -in CF.
Interestingly, while this study was underway, a second study from Strazzabosco lab reported [54] that the combination of correctors and PP2 in Mice studies: All procedures in mice were performed in compliance with institutional guidelines and were approved by CCHMC's IACUC.
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